QVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTGGGGSHHHHHHHHHH
＞95% by SDS-PAGE
12 months from date of receipt, -20 ℃to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. Please avoid repeated freeze-thaw cycles.
Erbb2 is a member of the human epidermal growth factor receptor family. Amplification or over-expression of Erbb2 has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. It is strongly associated with increased disease recurrence and a poor prognosis. Over-expression of Erbb2 is also known to occur in ovarian, stomach, adenocarcinoma of the lung and aggressive forms of uterine cancer. Due to its critical role in cancer development and progression, Erbb2 is the target of the monoclonal antibody trastuzumab.
Immobilized Human Erbb2, His Tag at 2 μg/mL (50 μL/well) can bind Anti-Human HER2(Pertuzumab) Monoclonal Antibody with EC50 of 24.98-28.27 ng/ ml.
您现在的位置：
